19 June 2013
Keywords: USA, New drug approvals, FDA, Burrill & Co
Article | 02 August 2011
The July approval of AstraZeneca’s blood-thinner Brilinta (ticagrelor), a potential blockbuster that will compete against Sanofi/Bristol-Myers Squibb& ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.